Angiolo Gadducci - Gynecology

Author Information

Angiolo Gadducci is affiliated with the Department of Clinical and Experimental Medicine, Division of Gynecology and Obstetrics, University of Pisa, Italy. His research primarily focuses on gynecological oncology, addressing various aspects of ovarian cancer, endometrial cancer, and other gynecological malignancies.

Research Contributions

Angiolo Gadducci has made significant contributions to the field of gynecological oncology, particularly in the study of ovarian and endometrial cancers. His work spans a variety of topics, including chemotherapy response, the role of imaging techniques in cancer treatment, and the impact of molecular markers on clinical outcomes. Notable studies include investigations into the efficacy and safety of platinum-based therapies, the prognostic relevance of PET/CT parameters, and the effects of PARP inhibitors and immune checkpoint inhibitors in the treatment of advanced ovarian carcinoma. His research frequently involves multicenter and single-center studies, reflecting a broad collaborative effort within the Italian medical community.

Aliases

Angiolo Gadducci is also known by the aliases A Gadducci and A. Gadducci in various publications.

Publication and Citation Metrics

Metric	Value
Total Papers	571
Total Citations	11054
H-index	60

Publications:

Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study

DOI: 10.21873/anticanres.15681

Year: 2022

Computed Tomography-assessed Skeletal Muscle Index and Skeletal Muscle Radiation Attenuation in Patients With Ovarian Cancer Treated With Primary Surgery Followed by Platinum-based Chemotherapy: A Single-center Italian Study

DOI: 10.21873/anticanres.15554

Year: 2022

Adjuvant chemotherapy in early-stage endometrioid endometrial cancer with >50% myometrial invasion and negative lymph nodes

DOI: 10.1136/ijgc-2020-002094

Year: 2021

750P Safety and efficacy of platinum desensitization treatment in patients with ovarian cancer and platinum hypersensitivity

DOI: 10.1016/j.annonc.2021.08.1192

Year: 2021

The Role of Skin Tests in the Prevention and Diagnosis of Hypersensitivity Reactions to Platinum Agents in Gynecological Cancer: A Single-Center Italian Retrospective Study

DOI: 10.3390/cancers13215468

Year: 2021

852 Molecular landscape in high-grade serous ovarian cancer: the correlation between BRCA mutational status and stromal p16 expression

DOI: 10.1136/ijgc-2021-esgo.599

Year: 2021

Perineural Invasion Correlates With Common Pathological Variables and Clinical Outcomes of Patients With Squamous Cell Carcinoma of the Vulva Treated With Primary Radical Surgery and Inguinal-femoral Lymphadenectomy

DOI: 10.21873/invivo.12349

Year: 2021

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.

DOI: 10.1016/S1470-2045(20)30637-9

Year: 2021

Randomized Clinical Trials and Real World Prospective Observational Studies on Bevacizumab, PARP Inhibitors, and Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Ovarian Carcinoma: A Critical Review

DOI: 10.21873/anticanres.15281

Year: 2021

Have Volume-based Parameters of Positron Emission Tomography/Computed Tomography Prognostic Relevance for Patients With Potentially Platinum-responsive Recurrent Ovarian Cancer? A Single Center Italian Study

DOI: 10.21873/anticanres.14960

Year: 2021

What is Hydrosalpinx?

Are Douches Safe?

What Role Does Insurance Play?

When should one seek medical advice?

What About Birth Control and Family Planning?

What are the Advantages of CT Scans?

What is a Vaginal Hysterectomy?

What is the Cost of IVF?

What is a Vulvar Biopsy?

Who Should Get a DEXA Scan?

Partnered Content Networks

Relevant Topics